Items where authors include "Mainz, J.G."

Article

Caley, L.R. orcid.org/0000-0001-8957-1018, Gillgrass, L., Zagoya, C. et al. (5 more authors) (2025) Longer term follow-up of abdominal symptoms (CFAbd-Score) after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis. Journal of Cystic Fibrosis, 24 (4). pp. 787-791. ISSN 1569-1993

Simmonds, N.J., Southern, K.W., De Wachter, E. et al. (26 more authors) (2024) ECFS standards of care on CFTR-related disorders: Identification and care of the disorders. Journal of Cystic Fibrosis, 23 (4). pp. 590-602. ISSN 1569-1993

Burgel, P.-R., Ballmann, M., Drevinek, P. et al. (8 more authors) (2024) Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy. BMJ Open Respiratory Research, 11 (1). e002049. ISSN 2052-4439

Mainz, J.G., Zagoya, C., Polte, L. et al. (12 more authors) (2023) Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score. Frontiers in Pharmacology, 14. 1207356. ISSN 1663-9812

Conference abstract

Caley, L. orcid.org/0000-0001-8957-1018, Zagoya, C., White, H. et al. (3 more authors) (2025) Associations between changes in CFAbd-Score, dietary intake and weight following Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy: preliminary analysis. [Conference abstract]

Gillgrass, L., Caley, L. orcid.org/0000-0001-8957-1018, Zagoya, C. et al. (5 more authors) (2024) P318 Abdominal symptoms after longer term use of elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis. [Conference abstract]

Mainz, J.G., Zagoya, C., Polte, L. et al. (12 more authors) (2022) WS02.01 Abdominal symptoms significantly decline after 24 weeks of elexacaftor/tezacaftor/ivacaftor treatment: first results obtained with the cystic fibrosis-specific CFAbd-Score in Germany and the UK. [Conference abstract]

Caley, L.R. orcid.org/0000-0001-8957-1018, Zagoya, C., White, H. et al. (3 more authors) (2022) P177 Adults with Cystic Fibrosis-Related Diabetes have a significantly elevated rate of gastrointestinal symptoms assessed with the CFAbd-Score. [Conference abstract]